Novo Nordisk closed the deal to buy Dicerna Pharmaceuticals Dicerna Pharmaceuticals from 12/28/21

User image

Vladimir Petenev

News editor
press@blackterminal.com

Novo Nordisk completed its acquisition of Dicerna Pharmaceuticals for $3.3 billion, or $38.25 per share.

Dicerna Pharmaceuticals

Review

Source:

{source} pictogram

novonordisk.com

Vladimir Petenev

News editor

Write your comment first

News feed

Board of Directors of Magnit recommended that dividends be paid for 2023

5/31/24 MGNT

Shareholders of MOEX Group approved dividends for 2023

5/31/24 MOEX

Softline acquires 51% of business automation platform

5/31/24 SOFL

InternSheep has opened a round of investment raising

5/31/24 OTCI

Shareholders of Rosseti Ural approved dividends for 3 months 2024

5/31/24 MRKU

Shareholders of Rosseti Ural approved dividends for 2023

5/31/24 MRKU

Shareholders of Magnitogorsk Iron and Steel Works approved dividends for 2023

5/31/24 MAGN

TMK announced the price range of the SPO

5/31/24 TRMK

Bashneft reports 3 months of 2024 by IFRS

5/31/24 BANE

Rosneft reports for 3 months of 2024 by IFRS

5/31/24 ROSN